MARKET

LPCN

LPCN

Lipocine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.395
+0.035
+2.57%
Opening 10:46 06/24 EDT
OPEN
1.420
PREV CLOSE
1.360
HIGH
1.430
LOW
1.390
VOLUME
554.81K
TURNOVER
--
52 WEEK HIGH
2.420
52 WEEK LOW
1.020
MARKET CAP
123.17M
P/E (TTM)
-4.5994
1D
5D
1M
3M
1Y
5Y
--Cantor Fitzgerald Starts Lipocine at Overweight With $3 Price Target
MT Newswires · 7h ago
Lipocine Announces Presentations at The International Liver Congress™ 2021 Digital Event
/PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data will be presented at The International Liver Congress™ 2021, the annual meeting of the...
PR Newswire - PRF · 1d ago
Lipocine To Present At The Raymond James Human Health Innovation Conference
/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Raymond James Human Health Innovation Conference. The conference wil...
PR Newswire - PRF · 06/16 12:00
Lipocine To Start Testing Neuro-Steroid Candidate In Postpartum Depression Patients
Benzinga · 06/14 13:37
Thinking about buying stock in Mereo BioPharma, Lipocine, Lordstown Motors, Sorrento Therapeutics, or Axcella Health?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MREO, LPCN, RIDE, SRNE, and AXLA.
PR Newswire - PRF · 06/14 13:31
BRIEF-FDA Clears LPCN 1154 IND Application For A Phase 2 Postpartum Depression Study
reuters.com · 06/14 12:37
Lipocine soars 9% on FDA greenlight for Phase 2 LPCN 1154 study in postpartum depression
Lipocine (LPCN) jumps 9% premarket after announcing that the FDA has cleared its IND application to initiate a Phase 2 study to evaluate the therapeutic potential of LPCN 1154, an oral neuro-steroid
Seekingalpha · 06/14 12:25
Lipocine Announces FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the
Benzinga · 06/14 12:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LPCN. Analyze the recent business situations of Lipocine through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LPCN stock price target is 5.00 with a high estimate of 10.00 and a low estimate of 2.500.
EPS
Institutional Holdings
Institutions: 62
Institutional Holdings: 8.50M
% Owned: 9.63%
Shares Outstanding: 88.29M
TypeInstitutionsShares
Increased
10
311.64K
New
15
414.18K
Decreased
9
345.32K
Sold Out
7
629.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.80%
Pharmaceuticals & Medical Research
+1.49%
Key Executives
Chairman/President/Chief Executive Officer/Director
Mahesh Patel
Chief Financial Officer/Executive Vice President
Morgan Brown
Vice President
Nachiappan Chidambaram
Lead Director/Independent Director
Stephen Hill
Director
John Higuchi
Independent Director
Jeffrey Fink
Independent Director
Richard Ono
No Data
About LPCN
Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products. The Company's primary development programs are based on oral delivery solutions for bioavailable drugs. The Company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitates lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminates gastrointestinal interactions that limit bioavailability. Its lead product candidate, TLANDO, is an oral testosterone replacement therapy. Its additional pipeline includes, an oral androgen therapy for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, LPCN 1144; a once daily oral testosterone replacement therapy, TLANDO XR (LPCN 1111); an androgen therapy for the treatment of NASH cirrhosis, LPCN 1148, and an oral therapy for the prevention of preterm birth, LPCN 1107.

Webull offers kinds of Lipocine Inc stock information, including NASDAQ:LPCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LPCN stock methods without spending real money on the virtual paper trading platform.